September 22, 2021
September 22, 2021 – Jakafi® (ruxolitinib) is now FDA approved to treat chronic graft-versus-host disease (cGVHD) in patients who are at least 12 years old and have failed
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
September 21, 2021
September 21, 2021 – Samsung Bioepis and Biogen's ByoovizTM (ranibizumab-nuna) has received U.S. FDA approval as a biosimilar for Genentech's Lucentis® (ranibizumab)
September 21, 2021
September 21, 2021 – OpzeluraTM (ruxolitinib) cream, manufactured by Incyte, has won U.S. FDA approval to treat mild to moderate atopic dermatitis in non-immunocompromised
September 20, 2021
September 20, 2021 – TivdakTM (tisotumab vedotin-tftv) is now U.S. FDA approved to treat recurrent or metastatic cervical cancer in patients whose disease has progressed
September 20, 2021
December 20, 2021 – YusimryTM (adalimumab-aqvh), manufactured by Coherus BioSciences, has been
approved as a biosimilar for AbbVie's Humira® (adalimumab)
September 16, 2021
September 16, 2021 – Takeda's ExkivityTM (mobocertinib) has received U.S. FDA approval to treat adults
who have locally advanced or metastatic
September 16, 2021
September 16, 2021 – Pfizer is now recalling all lots of Chantix® (varenicline) 0.5mg and 1mg tablets in the United States due to excess levels of a nitrosamine called
September 16, 2021
September 16, 2021 – The U.S. FDA has approved two new indications for Brukinsa® (zanubrutinib), the first to treat adults who have Waldenström's macroglobulinemia